// App-Quantinova.ai

P236 : Baricitinib provides better pain relief across all disease activity levels compared with placebo and adalimumab in RA

Researchers

Presenter

  • Peter C Taylor (Presenter)

Principal Investigators

  • Janet Pope

  • Kei Ikeda

  • Xiang Zhang

  • Bochao Jia

  • Hong Zhang

  • Amanda Quebe

  • Yun-Fei Chen

  • Carol L Kannowski

  • Thorsten Holzkaemper

  • Anabela Cardoso

  • Anthony Sebba

Medical Centers

  • Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Headington, UNITED KINGDOM

  • Department of Medicine, St. Joseph’s Health Care, London, ON, CANADA

  • Chiba University Hospital, Chiba University Hospital, Chiba, JAPAN

  • Eli Lilly and Company, Eli Lilly and Company, Indianapolis, IN

  • TechData Service, TechData Service, King of Prussia, PA

  • University of South Florida, University of South Florida, Tampa, FL

Locations

  • United Kingdom

  • Canada

  • Japan

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Malondialdehyde

Drug/Treatment

  • Baricitinib

  • Adalimumab

  • BARI

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved